Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576949 · ClinicalTrials.gov registry record · Phase 3
A Study of Cytisinicline for Smoking Cessation in Adult Smokers
A Phase 3 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 810
- Enrollment target
NCT04576949: Completed Phase 3 study, sponsored by Achieve Life Sciences.
NCT04576949 is a Phase 3 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 810 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04576949, a Phase 3 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 810 participants
- Enrollment target
Study Summary
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
Primary Outcome
Smoking abstinence as verified by weekly expired carbon monoxide (CO) measurements ≤10 parts per million (ppm).
Interventions
- DRUG Placebo
- DRUG Cytisinicline
- BEHAVIORAL Behavioral support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2021-12-23 |
| Phase | Phase 3 |
What the finished NCT04576949 record still lists
NCT04576949 is an interventional study that assigns participants to a tested intervention. The registered 810 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04576949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04576949 about?
NCT04576949 is a clinical study titled "A Study of Cytisinicline for Smoking Cessation in Adult Smokers". This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
What is the current status of trial NCT04576949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 810 participants. The study started on 2020-10-13. Estimated completion is 2021-12-23.
What interventions are being tested in trial NCT04576949?
The interventions under investigation include: Placebo (DRUG), Cytisinicline (DRUG), Behavioral support (BEHAVIORAL).
Who is sponsoring clinical trial NCT04576949?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04576949's enrollment target sits among peer trials
810 409th of 2000 higher than 1,591 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI